A Phase II Randomized, Double-blind, Placebo-controlled, Cross-over Study With Exploratory Outcomes of Fucose Supplementation in GLUT1 Deficiency Syndrome
A Phase II Randomized, Double-blind, Placebo-controlled, Cross-over Study With Exploratory Outcomes of Fucose Supplementation in GLUT1 Deficiency Syndrome
This is a single-center, randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of L-fucose supplementation in subjects with GLUT1 deficiency syndrome (GLUT1DS).
Inclusion Criteria:
Exclusion Criteria:
Inability to swallow liquids
Change in neurological medications (either medication itself or medication dosages) in the past 90 days
Use of fucose- or mannose-containing supplements within one year of enrollment
Presence of hepatic, renal, hematological, or concomitant metabolic disorders, as assessed by the presence of a previous diagnosis of such disorders (for instance, chronic kidney disease, liver cirrhosis, diabetes mellitus) or by the following laboratory values, which will be considered if obtained clinically up to 90 days before enrollment (if this is not available, laboratory tests will be obtained prior to first study visit):
Subjects who are pregnant, breastfeeding, or planning to become pregnant within one year of enrollment
Enrollment in an investigational new drug trial for G1DS within one year of enrollment
byerlee@ohsu.edu503-494-7004